References
- National diabetes fact sheet: general information and national estimates on diabetes in the United States, 2007. Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, 2008. Available at: http://www.cdc.gov/diabetes/pubs/pdf/ndfs_2007.pdf [Last accessed 25 September 2009]
- American Diabetes Association. Standards of medical care in diabetes – 2008 (position statement). Diabetes Care 2008;31:S12-S54
- Koro CE, Bowlin SJ., Bourgeois N, et al. Glycemic control from 1988 to 2000 among U.S. adults diagnosed with type 2 diabetes: a preliminary report. Diabetes Care 2004;27:17-20
- Nathan DM, Buse JB, Davidson MB, et al. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2006;29:1963-72
- Peyrot M, Rubin RR, Lauritzen T, et al. Resistance to insulin therapy among patients and providers. Diabetes Care 2005;28:2673-9
- Riddle MC, Rosenstock J, Gerich J. The treat-to-target trial. Diabetes Care 2003;26:3080-6
- Holman RR, Thorne KI, Farmer AJ, et al. Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. N Engl J Med 2007;357:1716-30
- Boccuzzi SJ, Sung JCY, Wogen J, et al. Utilization of oral hypoglycemic agents in a drug-insured U.S. population. Diabetes Care 2001;24:1411-15
- Cramer JA. A systematic review of adherence with medications for diabetes. Diabetes Care 2004;27:1218-24
- Cramer JA, Benedict A, Muszbek N, et al. The significance of compliance and persistence in the treatment of diabetes, hypertension and dyslipidaemia: a review. Int J Clin Pract 2008;62:76-87
- Balkrishnan R, Rajagopalan R, Camacho FT, et al. Predictors of medication adherence and associated health care costs in an older population with type 2 diabetes mellitus: a longitudinal cohort study. Clin Ther 2003;25:2958-71
- Erickson TN, Devine EB, O’Young TS, et al. Effect of switching medically vulnerable patients with uncontrolled diabetes from isophane insulin human to insulin glargine. Am J Health Syst Pharm 2006;63:1862-71
- Heine RJ, Van Gaal LF, Johns D et al., for the GWAA study group. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes. Ann Intern Med 2005;143:559-69
- Horvath K, Jeitler K, Berghold A, et al. Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus. The Cochrane Library 2007 Apr 18:CD005613
- Hermansen K, Clauson P, Davies M, et al. on behalf of the Levemir Treat-to-Target study group. A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin naive people with type 2 diabetes. Diabetes Care 2006;29:1269-74
- Rosenstock J, Schwartz SL, Clark CM Jr, et al. Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin. Diabetes Care 2001;24:631-36
- Donnelly LA, Morris AD, Evans JMM. Adherence to insulin and its association with glycaemic control in patients with type 2 diabetes. QJM 2007;100:345-50
- Piette JD. Problems paying out-of-pocket medication costs among older adults with diabetes. Diabetes Care 2004;27:384-91
- Roblin DW, Platt R, Goodman MJ, et al. Effect of increased cost-sharing on oral hypoglycemic use in five managed care organizations. Med Care 2005;43:951-9